159 related articles for article (PubMed ID: 38019741)
21. The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators.
Craig Jordan V; McDaniel R; Agboke F; Maximov PY
Steroids; 2014 Nov; 90():3-12. PubMed ID: 24949934
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
23. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
[TBL] [Abstract][Full Text] [Related]
24. Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.
Kastrati I; Semina S; Gordon B; Smart E
Mol Cell Endocrinol; 2019 Mar; 483():97-101. PubMed ID: 30659843
[TBL] [Abstract][Full Text] [Related]
25. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen for breast cancer.
Med Lett Drugs Ther; 1978 May; 20(9):41-2. PubMed ID: 642872
[No Abstract] [Full Text] [Related]
28. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
29. MRP as a new predictive marker of tamoxifen efficiency in treatment of estrogen receptor-positive breast cancer.
Bogush TA; Dudko EA; Bogush EA; Tikhomirov MV; Yu Kirsanov V; Davydov MI
Dokl Biochem Biophys; 2010; 430():36-40. PubMed ID: 20380160
[No Abstract] [Full Text] [Related]
30. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
31. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
32. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA
J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513
[TBL] [Abstract][Full Text] [Related]
33. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
[TBL] [Abstract][Full Text] [Related]
34. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
Peng J; Sengupta S; Jordan VC
Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen for patients with estrogen receptor-negative breast cancer.
Swain SM
J Clin Oncol; 2001 Sep; 19(18 Suppl):93S-97S. PubMed ID: 11560981
[No Abstract] [Full Text] [Related]
36. CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM; Carey LA; McLeod HL
Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: new tricks for an old dog?
Gelmann EP
J Natl Cancer Inst; 1996 Mar; 88(5):224-6. PubMed ID: 8613997
[No Abstract] [Full Text] [Related]
38. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
Robertson JF
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):209-12. PubMed ID: 11850227
[TBL] [Abstract][Full Text] [Related]
39. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Iddon J; Bundred NJ
Expert Rev Anticancer Ther; 2008 Jan; 8(1):9-13. PubMed ID: 18095878
[TBL] [Abstract][Full Text] [Related]
40. The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century.
Singh MN; Martin-Hirsch PL; Martin FL
Med Sci Monit; 2008 Sep; 14(9):RA144-8. PubMed ID: 18758431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
